{"id":38319,"date":"2026-08-28T12:09:01","date_gmt":"2026-08-28T10:09:01","guid":{"rendered":"https:\/\/www.etap-lab.com\/?post_type=ressource&#038;p=38319"},"modified":"2026-09-10T16:16:24","modified_gmt":"2026-09-10T14:16:24","slug":"poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions","status":"publish","type":"ressource","link":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/","title":{"rendered":"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Joint poster with BACOBA on &#8220;Lefleuganan for treatment of chronic inflammatory skin conditions<\/strong>&#8221; presented by Jean-Fran\u00e7ois Bisson at the annual meeting of the European Society for Dermatological Research (ESDR) in Heidelbeg (Germany) in September 2026.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-primary\"><a class=\"wp-block-button__link wp-element-button\" href=\"mailto:marketing@etap-lab.com?subject=Poster%20Request%20-%20ETAP-LAB%20-ESDR-Heidelberg-2026%20&amp;body=Hello%2C%20%0ACan%20you%20send%20me%20the%20poster%20dealing%20with%20Dermatology%20Research%20presented%20at%20ESDR-Heidelberg.%20Thank%20you.%20\">EASY POSTER REQUEST<\/a><\/div>\n<\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Authors<\/strong>: M. Kemmler<sup>1<\/sup>, A.T. Zizzari<sup>1<\/sup>, M. Adams<sup>1<\/sup>, L. Magadoux<sup>2<\/sup>, L. Razafitrimo<sup>2<\/sup>, J.-F. Bisson<sup>2<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Affiliations<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>1 Bacoba AG. Einsiedlerstrasse 32, 8820 W\u00e4denswil, Switzerland<\/li>\n\n\n\n<li>2 ETAP-Lab, D\u00e9partement de Dermatologie, Vandoeuvre-l\u00e8s-Nancy, France<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Abstract<\/strong>:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic inflammatory skin conditions are difficult to cure, long-lasting disorders causing persistent symptoms like itching, redness, and pain. They are primarily driven by a self-sustaining loop of inflammation generated by overactive T-cells &#8211; the type of T-cell involved often determining the type of skin condition. <strong>Lefleuganan is a clinical stage compound<\/strong> acting via a novel mode of action to achieve immune cell silencing to target overactive T-cells in an unprecedented way. The purpose of this study was to validate the treatment effect of topical Lefleuganan <strong>in <a href=\"https:\/\/www.etap-lab.com\/en\/cro-services\/dermatology\/in-vivo-models\/#cat-168\">translational models for chronic inflammatory skin<\/a> conditions driven by different T cell sub-populations<\/strong>. With a focus on the Th1\/Th17 axis, <strong>a <a href=\"https:\/\/www.etap-lab.com\/en\/cro-services\/dermatology\/in-vivo-models\/#cat-168\">model of imiquimod-induced psoriasis<\/a><\/strong> was selected together <strong>with a <a href=\"https:\/\/www.etap-lab.com\/en\/cro-services\/dermatology\/in-vivo-models\/#cat-168\">model of DNCB-induced atopic dermatitis<\/a> <\/strong>representing Th2 type inflammation. In both models, BALB\/c mice were treated for 7 days with topical Lefleuganan (as its formulation BAP5191) at concentrations between 0.03% and 1.0% together with active corticosteroid comparators (Clobetasol and Betamethasone) and controls. While all formulations showed beneficial effects, particularly the higher doses of 0.3% and especially 1.0% Lefleuganan demonstrated significant therapeutic benefits across clinical, behavioral and biological parameters that were comparable with the effects of reference treatments but without the corticosteroid associated side effects like skin atrophy or weight loss. Lefleuganan treatment effectively reduced clinical PASI scores (psoriasis) and ADASI scores (atopic dermatitis), improved skin barrier integrity (as indicated by lower TEWL), normalized key inflammatory markers like IL-17 and IL-6, and improved microscopic skin pathology findings. Behavioral assessments\u2014including licking, scratching, rearing, and locomotion\u2014further supported their efficacy. <strong>All Lefleuganan formulations were very well tolerated and could become promising new treatments for chronic inflammatory skin conditions.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Joint poster with BACOBA on &ldquo;Lefleuganan for treatment of chronic inflammatory skin conditions&rdquo; presented by Jean-Fran&ccedil;ois Bisson at the annual meeting of the European Society for Dermatological Research (ESDR) in Heidelbeg (Germany) in September 2026. Authors: M. Kemmler1, A.T. Zizzari1, M. Adams1, L. Magadoux2, L. Razafitrimo2, J.-F. Bisson2 Affiliations: Abstract: Chronic inflammatory skin conditions are [&hellip;]<\/p>\n","protected":false},"featured_media":38150,"template":"","meta":{"_acf_changed":false},"categorie-de-ressource":[236],"marque-de-ressource":[241],"class_list":["post-38319","ressource","type-ressource","status-publish","has-post-thumbnail","hentry","categorie-de-ressource-posters","marque-de-ressource-skinaxis"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions - ETAP-LAB<\/title>\n<meta name=\"description\" content=\"Joint poster with BACOBA on &quot;Lefleuganan for treatment of chronic inflammatory skin conditions&quot; presented by Jean-Fran\u00e7ois Bisson at the annual meeting of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions - ETAP-LAB\" \/>\n<meta property=\"og:description\" content=\"Joint poster with BACOBA on &quot;Lefleuganan for treatment of chronic inflammatory skin conditions&quot; presented by Jean-Fran\u00e7ois Bisson at the annual meeting of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/\" \/>\n<meta property=\"og:site_name\" content=\"ETAP-LAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-10T14:16:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Poster-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2151\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/\",\"name\":\"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions - ETAP-LAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ETAP-Ressources-Poster-1.jpg\",\"datePublished\":\"2026-08-28T10:09:01+00:00\",\"dateModified\":\"2026-09-10T14:16:24+00:00\",\"description\":\"Joint poster with BACOBA on \\\"Lefleuganan for treatment of chronic inflammatory skin conditions\\\" presented by Jean-Fran\u00e7ois Bisson at the annual meeting of\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ETAP-Ressources-Poster-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/ETAP-Ressources-Poster-1.jpg\",\"width\":2151,\"height\":1200,\"caption\":\"Illustration for our scientific ressources and poster\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressource\\\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ressources\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/ressources\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Posters\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/categorie-de-ressource\\\/posters\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"name\":\"Etap Lab\",\"description\":\"CRO Services\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\",\"name\":\"Etap Lab\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"width\":550,\"height\":550,\"caption\":\"Etap Lab\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/etap-lab\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions - ETAP-LAB","description":"Joint poster with BACOBA on \"Lefleuganan for treatment of chronic inflammatory skin conditions\" presented by Jean-Fran\u00e7ois Bisson at the annual meeting of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/","og_locale":"en_US","og_type":"article","og_title":"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions - ETAP-LAB","og_description":"Joint poster with BACOBA on \"Lefleuganan for treatment of chronic inflammatory skin conditions\" presented by Jean-Fran\u00e7ois Bisson at the annual meeting of","og_url":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/","og_site_name":"ETAP-LAB","article_modified_time":"2026-09-10T14:16:24+00:00","og_image":[{"width":2151,"height":1200,"url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Poster-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/","url":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/","name":"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions - ETAP-LAB","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/#primaryimage"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/#primaryimage"},"thumbnailUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Poster-1.jpg","datePublished":"2026-08-28T10:09:01+00:00","dateModified":"2026-09-10T14:16:24+00:00","description":"Joint poster with BACOBA on \"Lefleuganan for treatment of chronic inflammatory skin conditions\" presented by Jean-Fran\u00e7ois Bisson at the annual meeting of","breadcrumb":{"@id":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/#primaryimage","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Poster-1.jpg","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/05\/ETAP-Ressources-Poster-1.jpg","width":2151,"height":1200,"caption":"Illustration for our scientific ressources and poster"},{"@type":"BreadcrumbList","@id":"https:\/\/www.etap-lab.com\/en\/ressource\/poster-lefleuganan-for-treatment-of-chronic-inflammatory-skin-conditions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.etap-lab.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ressources","item":"https:\/\/www.etap-lab.com\/en\/ressources\/"},{"@type":"ListItem","position":3,"name":"Posters","item":"https:\/\/www.etap-lab.com\/en\/categorie-de-ressource\/posters\/"},{"@type":"ListItem","position":4,"name":"POSTER: Lefleuganan for treatment of chronic inflammatory skin conditions"}]},{"@type":"WebSite","@id":"https:\/\/www.etap-lab.com\/en\/#website","url":"https:\/\/www.etap-lab.com\/en\/","name":"Etap Lab","description":"CRO Services","publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.etap-lab.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.etap-lab.com\/en\/#organization","name":"Etap Lab","url":"https:\/\/www.etap-lab.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","width":550,"height":550,"caption":"Etap Lab"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/etap-lab\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/ressource\/38319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/ressource"}],"about":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/types\/ressource"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media\/38150"}],"wp:attachment":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media?parent=38319"}],"wp:term":[{"taxonomy":"categorie-de-ressource","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/categorie-de-ressource?post=38319"},{"taxonomy":"marque-de-ressource","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/marque-de-ressource?post=38319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}